Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

In 30 seconds

This phase 1/2 clinical trial evaluated the chemotherapy-free combination of the KRAS G12D inhibitor HRS-4642 and PD-L1 blockade with adebrelimab in 48 previously treated patients with metastatic KRAS G12D-mutant pancreatic ductal adenocarcinoma. In the recommended phase 2 dose cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5); median progression-free survival was 5.7 months (95% CI, 4.0-7.5). No dose-limiting toxicities or treatment-related deaths occurred during dose escalation. The authors describe the regimen as tolerable, with antitumor activity warranting further investigation.

Key findings

• At the recommended phase 2 dose, confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5) among 37 patients.
• Disease control rate was 81.1% (95% CI, 64.8-92.0), and median duration of response was 6.9 months (95% CI, 4.8-8.6).
• Median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9).
• Hypercholesterolemia and anemia were the most common treatment-related adverse events, each occurring in 50%; no treatment-related deaths occurred.

Why it matters

Metastatic KRAS G12D-mutant pancreatic cancer remains a difficult setting, and this trial reports clinical activity for a chemotherapy-free targeted and immunotherapy combination in previously treated patients. The response and survival outcomes provide a rationale for further evaluation, while the phase 1/2 design and limited cohort mean the findings should be interpreted as preliminary rather than definitive evidence of benefit.

What to keep in mind

The phase 1/2 trial included a limited number of patients, and the reported outcomes are from a single-arm treatment evaluation without a comparator.